Medical College of Wisconsin
CTSICores SearchResearch InformaticsREDCap

Veronica H. Flood MD

Veronica H. Flood MD

Associate Professor

Institution: Medical College of Wisconsin
Department: Pediatrics
Division: Hematology/Oncology
Program: Hematology


Research Experience

  • Blood Coagulation Disorders
  • von Willebrand Disease
  • Clinical Expertise

  • Blood Coagulation Disorders
  • Coagulation Protein Disorders
  • Hematologic Diseases
  • Hematology
  • Hemorrhagic Disorders
  • Thrombosis
  • von Willebrand Disease
  • Publications

  • Variable content of von Willebrand factor mutant monomer drives the phenotypic variability in a family with von Willebrand disease. (Chen J, Hinckley JD, Haberichter S, Jacobi P, Montgomery R, Flood VH, Wong R, Interlandi G, Chung DW, L√≥pez JA, Di Paola J) Blood 2015 Jul 9;126(2):262-9 PMID: 26019279 PMCID: PMC4497966
  • Laboratory diagnosis of von Willebrand disease. (Roberts JC, Flood VH) Int J Lab Hematol 2015 May;37 Suppl 1:11-7 PMID: 25976955
  • New insights into genotype and phenotype of VWD. (Flood VH) Hematology Am Soc Hematol Educ Program 2014 Dec 5;2014(1):531-5 PMID: 25696906
  • Crucial role for the VWF A1 domain in binding to type IV collagen. (Flood VH, Schlauderaff AC, Haberichter SL, Slobodianuk TL, Jacobi PM, Bellissimo DB, Christopherson PA, Friedman KD, Gill JC, Hoffmann RG, Montgomery RR, Zimmerman Program Investigators) Blood 2015 Apr 2;125(14):2297-304 PMID: 25662333 PMCID: PMC4383803
  • Perils, problems, and progress in laboratory diagnosis of von Willebrand disease. (Flood VH) Semin Thromb Hemost 2014 Feb;40(1):41-8 PMID: 24338593 PMCID: PMC3987108
  • Vitamin B12 deficiency: the great masquerader. (Dobrozsi S, Flood VH, Panepinto J, Scott JP, Brandow A) Pediatr Blood Cancer 2014 Apr;61(4):753-5 PMID: 24115632
  • No increase in bleeding identified in type 1 VWD subjects with D1472H sequence variation. (Flood VH, Friedman KD, Gill JC, Haberichter SL, Christopherson PA, Branchford BR, Hoffmann RG, Abshire TC, Dunn AL, Di Paola JA, Hoots WK, Brown DL, Leissinger C, Lusher JM, Ragni MV, Shapiro AD, Montgomery RR) Blood 2013 May 2;121(18):3742-4 PMID: 23520336 PMCID: PMC3643771
  • Variability in platelet- and collagen-binding defects in type 2M von Willebrand disease. (Larsen DM, Haberichter SL, Gill JC, Shapiro AD, Flood VH) Haemophilia 2013 Jul;19(4):590-4 PMID: 23496210 PMCID: PMC3688679
  • Collagen binding provides a sensitive screen for variant von Willebrand disease. (Flood VH, Gill JC, Friedman KD, Christopherson PA, Jacobi PM, Hoffmann RG, Montgomery RR, Haberichter SL, Zimmerman Program Investigators) Clin Chem 2013 Apr;59(4):684-91 PMID: 23340442 PMCID: PMC3852672
  • Use of purified fibrinogen concentrate for dysfibrinogenemia and importance of laboratory fibrinogen activity measurement. (Franzblau EB, Punzalan RC, Friedman KD, Roy A, Bilen O, Flood VH) Pediatr Blood Cancer 2013 Mar;60(3):500-2 PMID: 23129109 PMCID: PMC4461026
  • Comparison of type I, type III and type VI collagen binding assays in diagnosis of von Willebrand disease. (Flood VH, Gill JC, Christopherson PA, Wren JS, Friedman KD, Haberichter SL, Hoffmann RG, Montgomery RR) J Thromb Haemost 2012 Jul;10(7):1425-32 PMID: 22507643 PMCID: PMC3809762
  • Critical von Willebrand factor A1 domain residues influence type VI collagen binding. (Flood VH, Gill JC, Christopherson PA, Bellissimo DB, Friedman KD, Haberichter SL, Lentz SR, Montgomery RR) J Thromb Haemost 2012 Jul;10(7):1417-24 PMID: 22507569 PMCID: PMC3809952
  • Intersection of mechanisms of type 2A VWD through defects in VWF multimerization, secretion, ADAMTS-13 susceptibility, and regulated storage. (Jacobi PM, Gill JC, Flood VH, Jakab DA, Friedman KD, Haberichter SL) Blood 2012 May 10;119(19):4543-53 PMID: 22431572 PMCID: PMC3362367
  • VWF mutations and new sequence variations identified in healthy controls are more frequent in the African-American population. (Bellissimo DB, Christopherson PA, Flood VH, Gill JC, Friedman KD, Haberichter SL, Shapiro AD, Abshire TC, Leissinger C, Hoots WK, Lusher JM, Ragni MV, Montgomery RR) Blood 2012 Mar 1;119(9):2135-40 PMID: 22197721 PMCID: PMC3311248
  • Von Willebrand disease in the United States: a perspective from Wisconsin. (Flood VH, Gill JC, Friedman KD, Bellissimo DB, Haberichter SL, Montgomery RR) Semin Thromb Hemost 2011 Jul;37(5):528-34 PMID: 22102196 PMCID: PMC3807766
  • Gain-of-function GPIb ELISA assay for VWF activity in the Zimmerman Program for the Molecular and Clinical Biology of VWD. (Flood VH, Gill JC, Morateck PA, Christopherson PA, Friedman KD, Haberichter SL, Hoffmann RG, Montgomery RR) Blood 2011 Feb 10;117(6):e67-74 PMID: 21148813 PMCID: PMC3056647
  • Absent collagen binding in a VWF A3 domain mutant: utility of the VWF:CB in diagnosis of VWD. (Flood VH, Lederman CA, Wren JS, Christopherson PA, Friedman KD, Hoffmann RG, Montgomery RR) J Thromb Haemost 2010 Jun;8(6):1431-3 PMID: 20345715 PMCID: PMC3892206
  • Common VWF exon 28 polymorphisms in African Americans affecting the VWF activity assay by ristocetin cofactor. (Flood VH, Gill JC, Morateck PA, Christopherson PA, Friedman KD, Haberichter SL, Branchford BR, Hoffmann RG, Abshire TC, Di Paola JA, Hoots WK, Leissinger C, Lusher JM, Ragni MV, Shapiro AD, Montgomery RR) Blood 2010 Jul 15;116(2):280-6 PMID: 20231421 PMCID: PMC2910611
  • Limitations of the ristocetin cofactor assay in measurement of von Willebrand factor function. (Flood VH, Friedman KD, Gill JC, Morateck PA, Wren JS, Scott JP, Montgomery RR) J Thromb Haemost 2009 Nov;7(11):1832-9 PMID: 19694940 PMCID: PMC3825106
  • Fibrinogen Hershey IV: a novel dysfibrinogen with a gammaV411I mutation in the integrin alpha(IIb)beta(3) binding site. (Flood VH, Al-Mondhiry HA, Rein CM, Alexander KS, Lovely RS, Shackleton KM, David LL, Farrell DH) Thromb Haemost 2008 Jun;99(6):1008-12 PMID: 18521501 PMCID: PMC4089099
  • Hemorrhagic disease of the newborn despite vitamin K prophylaxis at birth. (Flood VH, Galderisi FC, Lowas SR, Kendrick A, Boshkov LK) Pediatr Blood Cancer 2008 May;50(5):1075-7 PMID: 17957759
  • Incorporation of fibrin molecules containing fibrinopeptide A alters clot ultrastructure and decreases permeability. (Flood VH, Nagaswami C, Chernysh IN, Al-Mondhiry HA, Weisel JW, Farrell DH) Br J Haematol 2007 Jul;138(1):117-24 PMID: 17555455
  • The fibrinogen Aalpha R16C mutation results in fibrinolytic resistance. (Flood VH, Al-Mondhiry HA, Farrell DH) Br J Haematol 2006 Jul;134(2):220-6 PMID: 16846481
  • Sustained engraftment post bone marrow transplant despite anti-platelet antibodies in Glanzmann thrombasthenia. (Flood VH, Johnson FL, Boshkov LK, Thomas GA, Nugent DJ, Bakke AC, Nicholson HS, Tilford D, Brown MP, Godder KT) Pediatr Blood Cancer 2005 Dec;45(7):971-5 PMID: 15768382
  • Last update: 07/27/2015